Challans

Colorectal cancer is a common and deadly cancer in France, often spreading to the liver. About 30 to 60% of patients develop liver metastases, and only a small percentage can have these surgically removed right away. For those with tumors that cannot be surgically removed, treatments typically involve chemotherapy combined with targeted drugs like panitumumab or bevacizumab. This research investigates combining systemic chemotherapy with intra-arterial oxaliplatin to improve tumor response and survival in patients with liver-only metastatic colorectal cancer. The study compares intravenous oxaliplatin and intra-arterial oxaliplatin combined with LV5FU2 chemotherapy, with or without irinotecan and targeted therapies, as a first-line treatment. Oxaliplatin is given every 15 days either through a vein or directly into the liver artery. Other drugs include fluorouracil, folinic acid, panitumumab (for patients with specific genetic mutations), bevacizumab, and irinotecan. This treatment aims to improve response rates and reduce side effects compared to standard methods. Participants will undergo regular treatment cycles every 15 days and will be monitored for tumor progression over 24 months after randomization. Assessments include measuring tumor size and progression-free survival. Patients will also be closely monitored for side effects and treatment tolerance. The study aims to determine which treatment approach offers better control of liver metastases and longer survival for patients with colorectal cancer limited to the liver.